Table q1_q4_2022_prescription_drugs_intro_to

Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like E*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Eckson Labs, LLC	44118070010	Plexion Cleanser Strength: Sodium Sulfacetimide, sulfer 9.8%, 4.8% 285g Tube	2022-04-01	693.0000	None	1	12000	None	None	None	None	None	None	This product has an anticipated launch of April 1, 2022.	None
Eckson Labs, LLC	44118070260	Plexion Cloths Sodium Sulfacetamide, Sulfur 9.8%4.8% 60ct 4g per packet in 1 carton	2022-05-03	752.0000	None	1	6000	None	None	None	None	None	None	None	None
Eckson Labs, LLC	44118070302	Plexion Lotion Sulfur and Sulfacetamide Sodium 48mg98mg/g 57g in 1 bottle	2022-05-03	699.0000	None	1	9000	None	None	None	None	None	None	None	None
Eckson Labs, LLC	44118070430	Vytone Cream Hydrocortizone Acetate and Iodoquinol 19mg10mg/g 30ct 2gm packets in 1 carton	2022-05-03	854.0000	None	1	6000	None	None	None	None	None	None	None	None
Edenbridge Pharmaceuticals, LLC	42799095001	Vigabatrin Tablets USP 500mg 100CT	2022-12-12	10511.8900	None	1	12	None	None	None	None	None	None	The first shipments of this presentation of Vigabatrin are scheduled to ship on or around 12/22/22. This product was not acquired. Edenbridge is not the ANDA holder.	None
Eli Lilly and Company	00002147180	MOUNJARO 10 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Eli Lilly and Company	00002146080	MOUNJARO 12.5 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Eli Lilly and Company	00002145780	MOUNJARO 15 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Eli Lilly and Company	00002150680	MOUNJARO 2.5 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Eli Lilly and Company	00002149580	MOUNJARO 5 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Eli Lilly and Company	00002148480	MOUNJARO 7.5 mg/0.5 mL 4 single-dose pens	2022-06-02	974.3300	None	1	34500000	None	1	None	None	None	None	MOUNJAROTM (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MOUNJARO was approved by the FDA in May 2022. Based on diabetes prevalence data from CDC’s diabetes statistics report [https://www.cdc.gov/diabetes/data/statistics-report/index.html], approximately 33.6 to 35.4 million people have type 2 diabetes. The average of that range (34.5 million) is reflected in the Estimated Patients field. People with type 2 diabetes may or may not use MOUNJARO to manage their diabetes. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. For more information, see https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.	None
Exelan Pharmaceuticals, Inc.	76282071727	Pirfenidone Tablets 267mg 270ct	2022-08-02	6292.7000	None	1	100000	None	None	None	None	None	None	product not acquired	None
Exelan Pharmaceuticals, Inc.	76282071690	Pirfenidone Tablets 801mg 90ct	2022-08-02	6281.0500	None	1	100000	None	None	None	None	None	None	product not acquired	None